195 related articles for article (PubMed ID: 22438990)
1. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.
Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H
J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110
[TBL] [Abstract][Full Text] [Related]
3. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.
Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L
PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
5. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
Riccio AA; McCauley M; Langelier MF; Pascal JM
Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
[TBL] [Abstract][Full Text] [Related]
6. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
9. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
10. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
12. Screening and structural analysis of flavones inhibiting tankyrases.
Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
[TBL] [Abstract][Full Text] [Related]
13. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
[TBL] [Abstract][Full Text] [Related]
14. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
15. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939.
Kirby CA; Cheung A; Fazal A; Shultz MD; Stams T
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Feb; 68(Pt 2):115-8. PubMed ID: 22297980
[TBL] [Abstract][Full Text] [Related]
16. Zinc binding catalytic domain of human tankyrase 1.
Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
18. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
19. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
[TBL] [Abstract][Full Text] [Related]
20. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
